ReviewJournal of cardiothoracic surgery2026
Exploring mesenchymal stem cells as a novel therapeutic approach for HACEK endocarditis: a narrative review.
Review in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive research has investigated the therapeutic potential of mesenchymal stem cells (MSCs) in treating infectious diseases and mitigating tissue damage caused by these diseases. MSCs, along with their exosomes, present a promising avenue for combating infectious diseases, particularly HACEK endocarditis (HE). MSCs possess immunomodulatory properties and aid in tissue repair, while exosomes carry bioactive molecules. Antimicrobial peptides (AMPs) released by MSCs demonstrate efficacy against a broad spectrum of microorganisms, including bacteria, fungi, yeasts, and viruses. Key AMPs produced by MSCs include hepcidin, cathelicidin LL-37, and β-defensin-2. Furthermore, these AMPs have been found to interact with MSCs, influencing their proliferation, migration, and regeneration, indicating a broader biological impact than previously recognized. Preclinical studies have highlighted the potential of these AMPs to reduce inflammation, enhance cardiac function, and augment the efficacy of antibiotics against bacterial pathogens. This narrative review investigates the antimicrobial efficacy of MSCs, with specific emphasis on their therapeutic application against HACEK-associated infective endocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.